Acumen Pharmaceuticals

ABOS

Market cap $204M

The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript

NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) --  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2025 and provided a business update.

NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) --  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses.

NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET.

Acumen Pharmaceuticals, Inc. ( ABOS ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Alex Braun - VP & Head of Investor Relations Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - BofA Securities, Research Division Thomas Shrader - BTIG, LLC, Research Division Matthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and welcome to the Acumen Pharma Third Quarter 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this call may be recorded.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Presentation Unknown Analyst All right. Here we go.

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.